Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Biotechnology

Health & Wellness

Health Care

Pharmaceutical

Amolyt Pharma

Michael Culler

Clémentine Chalmey

Damien Aumaille

Delphine Martinez

Guillaume Ravel, PharmD, PhD, DABT

michel ovize

Benedicte Gagnere

Aurélie MILLERAT

Héloïse Boullet

Laetitia Ouafki

Patrick Loustau

Caroline Robo (Fesquet)

Blandine WEISS

Clinical Management Team

Leadership Team

CMC Team

Finance Team

Medical Affairs and Development

Regulatory and Quality Management

Teams at Amolyt Pharma